Transdermal drug delivery system

Abstract

A controlled release transdermal system for the delivery of at least one therapeutic agent comprises: a reservoir comprising (a) the therapeutic agent in ionized form and (b) a pH adjusting agent which upon uptake of water is converted to a buffer solution and (c) a cyclized polysaccharide selected from a group consisting of cyclodextrin, cyclodextrin derivative and cyclodextrin polymer, the cyclized polysaccharide being capable of improving the solubility of the therapeutic agent in the buffer solution by forming an inclusion complex with the therapeutic agent; and a reservoir wall comprising a polymer being substantially impermeable to the ionized form or to the inclusion complex form of the therapeutic agent but permeable to water and to the unionized form of the therapeutic agent. The system allows the release of a therapeutic agent which may be a weak acid or base in a manner which shows less variation between patients than previous systems.

Claims

1. A controlled release transdermal device for the delivery of a therapeutic agent, comprising a reservoir and a reservoir wall,

wherein said reservoir comprises:

(a) said therapeutic agent in the form of a solid-state salt,

(b) a solid-state pH-adjusting agent, wherein said agent is converted to a buffer solution upon uptake of water, and

(c) a cyclized polysaccharide selected from the group consisting of a cyclodextrin, a cyclodextrin derivative, and a cyclodextrin polymer, wherein said cyclized polysaccharide is capable of improving the solubility of said therapeutic agent in the buffer solution by forming an inclusion complex with said therapeutic agent; and

wherein said reservoir wall comprises a polymer, wherein said polymer is substantially impermeable to the ionized form or to the inclusion complex of said therapeutic agent but is permeable to water and to the unionized form of said therapeutic agent,

wherein the conversion of said solid-state pH-adjusting agent to the buffer solution determines the unionization of said therapeutic agent.

2. The transdermal device according to claim 1, wherein said cyclodextrin derivative is 2-hydroxypropyl-.beta.-cyclodextrin or 2-hydroxypropyl-.gamma.-cyclodextrin.

3. The transdermal device according to claim 1, wherein said therapeutic agent is dexmedetomidine.

4. The transdermal device according to claim 1, wherein said polymer in said reservoir wall is an elastomeric polymer.

5. The transdermal device according to claim 4, wherein said elastomeric polymer is selected from the group consisting of silicone polymers, polyisobutylene and siliconepolyethyleneoxide copolymers.

6. The transdermal device according to claim 1, wherein said reservoir is a single core containing said therapeutic agent, said cyclized polysaccharide and said solid-state pH-adjusting agent and said reservoir is surrounded by said reservoir wall.

7. The transdermal device according to claim 1, wherein said reservoir is a plurality of individual cores, each containing said therapeutic agent, said cyclized polysaccharide and said solid-state pH-adjusting agent, and each being surrounded by said polymer in said reservoir wall.

8. The transdermal device according to claim 1, wherein said device comprises a polymer matrix as said reservoir wall and contained in said matrix is a plurality of individual cores.

9. The transdermal device according to claim 1, wherein said device comprises a polymer membrane as said reservoir wall.

10. The transdermal device according to claim 1, wherein said reservoir wall is loaded with said therapeutic agent.

11. The transdermal device according to claim 1, wherein said device further comprises a rate limiting polymer membrane loaded with said therapeutic agent.

12. A process for preparing the device according to claim 1, comprising creating a reservoir of said therapeutic agent said solid-state pH-adjusting agent and said cyclized polysaccharide and placing said reservoir in contact with said reservoir wall.

13. A method of transdermal drug delivery comprising administering to a patient a controlled release transdermal device according to claim 1.

14. The transdermal device according to claim 2, wherein said therapeutic agent is dexmedetomidine.

15. The transdermal device according to claim 2, wherein said polymer in the reservoir wall is an elastomeric polymer.

16. The transdermal device according to claim 2, wherein said reservoir is a single core containing said therapeutic agent, said cyclized polysaccharide and said solid-state pH-adjusting agent and said reservoir is surrounded by said reservoir wall.

17. The transdermal device according to claim 2, wherein said reservoir is a plurality of individual cores, each containing said therapeutic agent, said cyclized polysaccharide and said solid-state pH-adjusting agent, and each being surrounded by said polymer in said reservoir wall.

18. The transdermal device according to claim 2, wherein said device comprises a polymer matrix as said reservoir wall and contained in said matrix is a plurality of individual cores.

19. The transdermal device according to claim 2, wherein said device comprises a polymer membrane as said reservoir wall.

20. Transdermal device according to claim 9, wherein said reservoir wall is loaded with said therapeutic agent.

21. The transdermal device according to claim 7, wherein said device further comprises a rate limiting polymer membrane loaded with said therapeutic agent.

22. The transdermal device according to claim 1, wherein said solid-state pH-adjusting agent is a powder.

23. A controlled release transdermal device for the delivery of a therapeutic agent, comprising a reservoir and a reservoir wall,

wherein said reservoir comprises:

(a) said therapeutic agent in the form of a solid-state salt,

(b) a powder pH-adjusting agent, wherein said agent is converted to a buffer solution upon uptake of water, and

(c) a cyclodextrin derivative, wherein said cyclodextrin derivative is capable of improving the solubility of said therapeutic agent in the buffer solution by forming an inclusion complex with said therapeutic agent; and

wherein said reservoir wall comprises a semipermeable elastomeric polymer selected from the group consisting of silicone polymers, polyisobutylene and siliconepolyethyleneoxide copolymers,

wherein the conversion of said solid-state pH-adjusting agent to the buffer solution determines the unionization of said therapeutic agent.

24. The transdermal device according to claim 23, wherein said cyclodextrin derivative is 2-hydroxypropyl-.beta.-cyclodextrin or 2-hydroxypropyl-.gamma.-cyclodextrin.

25. The transdermal device according to claim 23, wherein said therapeutic agent is dexmedetomidine.